Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 38, (16363-16368) DOI: 10.1073/pnas.0904514106);Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 38, 2009, Pages 16363-16368

  Brantly, Mark L ^a   Chulay, Jeffrey D ^b   Wang, Lili ^c   Mueller, Christian ^d   Humphries, Margaret ^d   Spencer, L Terry ^e   Rouhani, Farshid ^a   Conlon, Thomas J ^f   Calcedo, Roberto ^c   Betts, Michael R ^c   Spencer, Carolyn ^e   Byrne, Barry J ^f   Wilson, James M ^c   Flotte, Terence R ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

AAV; CTL; Gene therapy; Immune response; Pulmonary

Indexed keywords

ALPHA 1 ANTITRYPSIN; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR;

ADULT; AGED; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDIDYMITIS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENOME; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE; TRANSGENE; VIRUS CAPSID; WILD TYPE;

ADENO-ASSOCIATED VIRUS; BACTERIA (MICROORGANISMS); MIRIDAE;

EID: 70349481529     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909220106     Document Type: Erratum

References (31)

1. Crystal RG (1989) The alpha 1-antitrypsin gene and its deficiency states. Trends Genet 5:411-417. (Pubitemid 20011533)
2. Crystal RG, et al. (1989) The alpha 1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest 95:196-208.
3. Ogushi F, et al. (1988) Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase. Am Rev Respir Dis 137:364-370. (Pubitemid 18050186)
4. Brantly ML, et al. (1991) Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest 100:703-708.
5. Ogushi F, Hubbard RC, Vogelmeier C, Fells GA, Crystal RG (1991) Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase. J Clin Invest 87:1060-1065.
6. Heresi GA, Stoller JK (2008) Augmentation therapy in alpha-1 antitrypsin deficiency. Expert Opin Biol Ther 8:515-526. (Pubitemid 351570414)
7. Kessler PD, et al. (1996)Genedelivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 93:14082-14087. (Pubitemid 26424249)
8. Levy MY, Barron LG, Meyer KB, Szoka FC, Jr (1996) Characterization of plasmid DNA transfer into mouse skeletal muscle: Evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Ther 3:201-211.
9. Clark KR, Sferra TJ, Johnson PR (1997) Recombinant adeno-associated viral vectors-mediate long-term transgene expression in muscle. Hum Gene Ther 8:659-669.
10. Song S, et al. (1998) Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 95:14384-14388. (Pubitemid 28549376)
11. Brantly ML, et al. (2006) Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 17:1177-1186.
12. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE (2001) Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther 4:217-222. (Pubitemid 32851285)
13. Flotte TR, Conlon TJ, Poirier A, Campbell-Thompson M, Byrne BJ (2007) Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum Gene Ther 18:245-256. (Pubitemid 46626463)
14. Manno CS, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347.
15. Mingozzi F, et al. (2007) Intramuscular administration of an AAV1 vector in humans results in capsid specific T cell responses. Mol Ther 15(Suppl 1):3400 (abstr).
16. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199:381-390.
17. Lu Y, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 17:625-634. (Pubitemid 43967866)
18. Gao G, et al. (2003) Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 100:6081-6086. (Pubitemid 36576934)
19. Gao GP, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99:11854-11859.
20. Constans J, et al. (1992) Clinical pharmacokinetics of alpha 1-antitrypsin inhomozygous PiZ deficient patients. Clin Pharmacokinet 23:161-168.
21. Fournel MA, Newgren JO, Betancourt CM, Irwin RG (1988) Preclinical evaluation of alpha-1-proteinase inhibitor. Pharmacokinetics and safety studies. Am J Med 84:43-47.
22. Zamora NP, et al. (2008) Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: From pharmacokinetic analysis to individualizing therapy. Ann Pharmacother 42:640-646.
23. Grimm D, Kern A, Rittner K, Kleinschmidt JA (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9:2745-2760. (Pubitemid 29027018)
24. Snyder RO, Flotte TR (2002) Production of clinical-grade recombinant adeno-associated virus vectors. Curr Opin Biotechnol 13:418-423. (Pubitemid 35379925)
25. Zolotukhin S, et al. (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28:158-167. (Pubitemid 35341079)
26. Poirier A, et al. (2004) Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-α1-antitrypsin vector. Preclinica 2:43-51.
27. Song S, et al. (2002) Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: Safety and immunologic aspects. Mol Ther 6:329-335. (Pubitemid 36305334)
28. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM (2008) Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 19:663-669. (Pubitemid 352009917)
29. Hernandez YJ, et al. (1999) Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 73:8549-8558.
30. Fu TM, et al. (2007) Evaluation of cellular immuneresponses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 23:67-76. (Pubitemid 46214174)
31. Betts MR, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.